Compare METC & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | METC | ALVO |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | Luxembourg |
| Employees | 900 | 1460 |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 998.6M |
| IPO Year | N/A | N/A |
| Metric | METC | ALVO |
|---|---|---|
| Price | $15.27 | $3.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $34.00 | $8.00 |
| AVG Volume (30 Days) | ★ 1.2M | 322.9K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.61 | $13.28 |
| Revenue Next Year | $11.96 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.51 | $3.03 |
| 52 Week High | $57.80 | $11.85 |
| Indicator | METC | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 52.80 |
| Support Level | $15.08 | $3.03 |
| Resistance Level | $15.98 | $3.93 |
| Average True Range (ATR) | 0.86 | 0.19 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 75.58 | 74.30 |
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. The company's two operating segments are Metallurgical Coal segment; and Rare Earths and Critical Minerals.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.